Table 6 Therapeutic management of cancer a in patients with CRNP
From: Cancer-related neuropathic pain in out-patient oncology clinics: a European survey
n = 310 | |
|---|---|
Chemotherapy, n (%) | |
No | 55 (17.74) |
Yesb | 194 (62.58) |
Radiotherapy, n (%) | |
No | 79 (25.48) |
Yes | 167 (53.87) |
Prior | 138 (44.52) |
Ongoing | 20 (6.45) |
Endocrine (hormone) therapy, n (%) | |
No | 149 (48.06) |
Yes | 69 (22.26) |
Prior | 17 (5.48) |
Ongoing | 49 (15.81) |
Multi-targeted substances, n (%) | |
No | 167 (53.87) |
Yes | 39 (12.58) |
Prior | 15 (4.84) |
Ongoing | 20 (6.45) |
Other, n (%) | |
No | 91 (29.35) |
Yes | 40 (12.90) |
Prior | 7 (2.26) |
Ongoing | 30 (9.68) |